脑啡肽原提升急性冠脉综合征心肾风险预测:KID-ACS评分
本研究在瑞士多中心急性冠脉综合征(ACS)前瞻性队列(n=4787)及英国、捷克、德国验证队列中评估血浆脑啡肽原(PENK)对住院急性肾损伤(AKI)和30天死亡的预测价值,并推导出六项KID-ACS评分进行外部验证。结果显示PENK独立关联住院AKI和30天死亡,KID-ACS评分在推导队列和验证队列中均表现出高预测性能,优于对照评分。
要点
- 血浆PENK独立预测ACS患者住院AKI和30天死亡。
- 六项KID-ACS评分同时评估肾脏和死亡风险,外部验证表现良好。
- KID-ACS评分预测性能优于CA-AKI评分和GRACE 2.0评分。
核心结论
- 循环PENK为ACS患者住院AKI和死亡预测提供增量价值。
- 简单的六项KID-ACS评分整合PENK,可同时评估肾脏和死亡风险。
研究设计与样本
- 前瞻性多中心ACS队列来自瑞士(n=4787),验证队列来自英国(n=1141)、捷克(n=927)和德国(n=220)。
- 推导并外部验证用于同时预测住院AKI和30天死亡的生物标志物增强风险评分(KID-ACS评分)。
主要发现
- 多变量调整既定风险因素后,PENK仍与住院AKI相关(每log2增加:调整OR 1.53,95%CI 1.13-2.09,P=.007)。
- 多变量调整后,PENK仍与30天死亡相关(调整HR 2.73,95%CI 1.85-4.02,P<.001)。
- 推导队列中KID-ACS评分预测住院AKI的AUC为.72(95%CI .68-.76),预测30天死亡的AUC为.91(95%CI .87-.95)。
- 外部验证中,KID-ACS预测住院AKI的AUC:苏黎世.73(95%CI .70-.77)、捷克.75(95%CI .68-.81)、德国.71(95%CI .55-.87)。
- 外部验证中,KID-ACS预测30天死亡的AUC:英国.87(95%CI .83-.91)、捷克.91(95%CI .87-.94)、德国.96(95%CI .92-1.00)。
关键数值与推荐
- KID-ACS评分预测住院AKI和30天死亡的性能分别优于对比剂相关AKI评分和GRACE 2.0评分。
临床怎么用
- KID-ACS评分可用于ACS患者住院期间同时评估肾脏和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Circulating proenkephalin (PENK) is a stable endogenous polypeptide with fast response to glomerular dysfunction and tubular damage. This study examined the predictive value of PENK for renal outcomes and mortality in patients with acute coronary syndrome (ACS). METHODS: Proenkephalin was measured in plasma in a prospective multicentre ACS cohort from Switzerland (n = 4787) and in validation cohorts from the UK (n = 1141), Czechia (n = 927), and Germany (n = 220). A biomarker-enhanced risk score (KID-ACS score) for simultaneous prediction of in-hospital acute kidney injury (AKI) and 30-day mortality was derived and externally validated. RESULTS: On multivariable adjustment for established risk factors, circulating PENK remained associated with in-hospital AKI [per log2 increase: adjusted odds ratio 1.53, 95% confidence interval (CI) 1.13-2.09, P = .007] and 30-day mortality (adjusted hazard ratio 2.73, 95% CI 1.85-4.02, P < .001). The KID-ACS score integrates PENK and showed an area under the receiver operating characteristic curve (AUC) of .72 (95% CI .68-.76) for in-hospital AKI and .91 (95% CI .87-.95) for 30-day mortality in the derivation cohort. Upon external validation, KID-ACS achieved similarly high performance for in-hospital AKI (Zurich: AUC .73, 95% CI .70-.77; Czechia: AUC .75, 95% CI .68-.81; Germany: AUC .71, 95% CI .55-.87) and 30-day mortality (UK: AUC .87, 95% CI .83-.91; Czechia: AUC .91, 95% CI .87-.94; Germany: AUC .96, 95% CI .92-1.00), outperforming the contrast-associated AKI score and the Global Registry of Acute Coronary Events 2.0 score, respectively. CONCLUSIONS: Circulating PENK offers incremental value for predicting in-hospital AKI and mortality in ACS. The simple six-item KID-ACS risk score integrates PENK and provides a novel tool for simultaneous assessment of renal and mortality risk in patients with ACS.
引用
- Wenzl, Wang, Arrigo, et al. Proenkephalin improves cardio-renal risk prediction in acute coronary syndromes: the KID-ACS score. Eur Heart J. 2025. PMID: 39215600. doi:10.1093/eurheartj/ehae602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。